Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana

14 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile

The mGlu5 receptor: a target for antagonists with improved anxiolytic activity

13 Jul 05

Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline

DailyUpdates: Breaking Journal Articles & Press Releases for the Drug Development Sector

08 Jul 05

DailyUpdates was developed in 2002 by the drug development consultants, LeadDiscovery. Developed for the R&D community, 1,000's of individuals plus many of the top 20 pharmaceutical companies now use this simple yet effective tool to track key events in the drug discovery sector.

Histone deacetylase inhibitors

06 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally designed with improved specificity

Aurora Kinase inhibitors

01 Jul 05

Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery

TherapeuticAdvance-June 2005

29 Jun 05

Welcome to the June edition of TherapeuticAdvances, LeadDiscovery's free newsletter for the drug development sector. Read on for editorial comment on selected studies recently featured on DailyUpdates our regular bulletin of breaking journal articles and drug development news

Chronic viral hepatitis: B is for billions

28 Jun 05

Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs. Current pipeline products are expected to account for 89% of total market sales by 2015, however other developmental antivirals are also expected to contribute significantly to future market growth, potentially resulting in new treatment paradigms.


17 Jun 05

The ancient Egyptians thought that diabetes was due to an ‘imbalance of the four bodily elements’ and that the best treatment to give these patients was a mixture of ground earth, water, wheat and lead. Thankfully, things have improved a little since then! In fact, the most important advance in diabetes management occurred in 1921 when the young surgeon Frederick Banting and the even younger medical student, Charles Best, first isolated insulin.
CSF Medical

How are your customers directed to work with you?

16 Jun 05

Don’t take it personally if customers seem more paranoid in your presence these days. There have been a number of directives governing their interaction with the pharmaceutical industry. This has made many of them uneasy and indeed uncertain about what they can do and say in the presence of a medical sales person.
Miriam George


08 Jun 05

Fewer than 10% of people state that they have never had a headache.1 A recent UK survey identified 7.6% of males and 18.3% of females with migraine within the preceding year.2 Prevalence of migraine was shown to vary with age, rising through early adult life and declining in the late 40s and early 50s. Migraineurs reported at least one migraine attack per month on average, and most experienced interference with daily activities in at least 50% of their attacks.
CSF Medical Communications

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.